Travere Therapeutics (TVTX) is up 13.2%, or $4.67 to $40.03.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Anticipated FILSPARI Approval and Strategic Initiatives
- Ligand initiated with a Buy at Citi
- Positive Outlook for Travere Therapeutics: Buy Rating Backed by Strong Clinical Data and Market Expansion Potential
- Optimistic Buy Rating for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Positioning
- Positive Outlook for Travere Therapeutics: FILSPARI’s Advancements in Reducing Proteinuria and Long-term Kidney Failure Risk